Millipore signs licensing agreement with Bayer HealthCare

Bayer HealthCare will use Millipore’s UCOE (Ubiquitous Chromatin Opening Element) technology to manufacture biologic drugs. The license will enable Bayer to more efficiently manufacture recombinant proteins in mammalian cells by generating higher protein yields in its upstream bioprocessing operations.

Andrew Bulpin, vice president of Millipore’s upstream bioprocessing business unit, said: “This license is another example of how we can help pharmaceutical and biotech companies efficiently manufacture biologic drugs for both commercial use and for use in clinical development.”